

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
6 February 2003 (06.02.2003)

PCT

(18) International Publication Number  
WO 03/010154 A1

- (51) International Patent Classification: C07D 233/12  
(52) International Application Number: PCT/KR01/01275  
(53) International Filing Date: 26 July 2001 (26.07.2001)  
(54) Filing Language: English  
(55) Publication Language: English  
(57) Abstract: (for all designated States except US): Seleno compounds containing nitron moiety, a process for preparing the same, the use of the same compounds as therapeutics for treating various medical dysfunctions and diseases caused by reactive oxygen species, in particular stroke, Parkinson's disease, and Alzheimer's disease.  
(72) Inventors: and  
(73) Applicant: (for US only): MD, Sang-De (KOR); 105-702 Dong-A Apartment, Haebyeong-3-dong, Chanhwa 200-163, Kangwon-do (KR), 1916, Myung-dong, Seonju-gu, Gangwon-do (KR), 200-180, Kangwon-do (KR)  
(74) Agent: LEE, Nam-Young; 105-702 Dong-A Apartment, Haebyeong-3-dong, Chanhwa 200-163, Kangwon-do (KR), 1916, Myung-dong, Seonju-gu, Gangwon-do (KR), 200-180, Kangwon-do (KR)  
(75) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, FR, GB, GR, GU, HK, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LI, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RU, SA, SD, SE, SG, SI, SK, SL, SV, TH, TM, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.  
(75) Designated States (regional): AKIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), EPO patent (AM, AZ, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR, UA, UG, UZ, VN, YU, ZA, ZW), OAPI patent (BF, BJ, CF, CG, CI, CM, GN, GU, GW, ML, MR, NE, NG, TD, TG, TN).  
(76) Published: with international search report  
(77) No international search report  
(78) No international search report  
(79) No international search report  
(80) No international search report  
(81) No international search report  
(82) No international search report  
(83) No international search report  
(84) No international search report  
(85) No international search report  
(86) No international search report  
(87) No international search report  
(88) No international search report  
(89) No international search report  
(90) No international search report  
(91) No international search report  
(92) No international search report  
(93) No international search report  
(94) No international search report  
(95) No international search report  
(96) No international search report  
(97) No international search report  
(98) No international search report  
(99) No international search report  
(100) No international search report

(54) Title: SELENO COMPOUNDS CONTAINING NITRON MOIETY, THEIR PREPARATION AND THEIR THERAPEUTIC USES



Sham Global ischemic control Example 5

(57) Abstract: The present invention provides novel seleno compounds containing nitron moiety, a process for preparing the same, the use of the same compounds as therapeutics for treating various medical dysfunctions and diseases caused by reactive oxygen species, in particular stroke, Parkinson's disease, and Alzheimer's disease. The compounds of the invention have been shown to be effective in inhibiting the production of reactive oxygen species, and in particular, the production of superoxide anion and hydroxyl radical. While showing lower toxicity and better water solubility, they also effectively inhibit the cerebral neuronal cell death caused by ROS and show neuroprotective effects against ischemic neuronal degeneration.

WO 03/010154

PCT/KR01/01275

2

Consequently, for some disorders associated with ageing, such as atherosclerosis, cataract, non-insulin-dependent diabetes, cancer or chronic neurodegenerative disorders, numerous studies have been able to demonstrate that such conditions are associated with those "oxidative stress" conditions.

The central nervous system is especially sensitive to "oxidative stress" because of its high oxygen consumption, the relatively low levels of its antioxidant defenses and the high iron concentration of some cerebral regions. This explains why "oxidative stress" might be one of the main etiological factors of cerebral ageing, as well as of acute central nervous system disorder such as stroke, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, and neurodegeneracies of the basal ganglia. The rate of occurrence of neurodegenerative disorders of central nervous system increases worldwide. Stroke occupies the third highest cause of death following cardiovascular diseases and malignant tumors (Ann: Parnetti, L. et al., Drug, and 53:752 (1997)).

Antioxidants protecting neuron cell of brain from oxidative stress include vitamin E derivatives such as Trolox (Ann: J. Med. Chem., 38:453 (1995)), glutathione peroxidase (hereinafter, referred to as "GPx") mimics (Ann: Daiichi Pharmaceutical Co., Ltd., Annual Report (1999); WO 9808031; USP 5008394; J. Am. Chem. Soc., 119:2079-2083 (1997); Adv. Pharmacol., 38:229 (1996)), superoxide dismutase (SOD) mimics (Ann: USP 5827880), and spin trapping agents (Ann: J. Med. Chem., 39:4988 (1996); USP 5475032).

A GPx mimic is a synthesized compound mimicking the function of the selenocystein from GPx active site. A well-known GPx mimic, Ebselen seems to have no major toxicity in preclinical and clinical tests and it is proposed as a potential drug for stroke. Ebselen is, however, very little soluble in water, even in the presence of an excess of glutathione (GSH), which limits

SELENO COMPOUNDS CONTAINING NITRON MOIETY,  
THEIR PREPARATION AND THEIR THERAPEUTIC USES

## 5 BACKGROUND OF THE INVENTION

## Field of the Invention

The present invention relates to novel seleno compounds containing nitron moiety, their preparation and pharmaceutical compositions containing the novel compounds as active ingredients, more particularly, to novel seleno compounds containing nitron moiety, a process for the preparation of the same, the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases caused by reactive oxygen species (ROS), in particular stroke, Parkinson's disease, and Alzheimer's disease.

## 20 Description of the Prior Art

According to Harman's free-radical theory of ageing, successive oxidation attacks create "oxidative stress" conditions, that is, create an imbalance between the protective systems in favour of the pro-oxidants. Such attacks result in numerous molecular modifications, especially of polyunsaturated membrane lipids, proteins and nucleic acids. Human and animal organisms possess various defense mechanisms that act in synergy. Those mechanisms are of an enzymatic nature (superoxide dismutase, catalase, and glutathione peroxidase) or of a non-enzymatic nature (such as vitamins E and C, which enable physiological control of free-radical activity). With ageing, however, that protection becomes less efficient, not to say inefficient, especially as a result of the decreased activity of a large number of enzymes including those involved in such defense mechanisms.

WO 03/010154

PCT/KR01/01275

3

its pharmacological applications.

Spin trapping agents may be developed as an antioxidant if they can trap hazardous free radicals enough, which include o-phenyl-N-tert-butyl nitron (PBN), and various derivatives of PBN have been developed. Generally, nitron moiety increases the solubility of compounds in water. However, it has revealed shortcomings such as a low lipid peroxidation inhibition activity in vitro and a low protection of brain cells in vivo (Ann: Favig, Thomas L. et al., J. Med. Chem., 39:4988-4996 (1996)).

## SUMMARY OF THE INVENTION

The present inventors synthesized novel compounds by introducing spin trapping agent, i.e., nitron moiety into GPx mimic, Ebselen, which have not only increased solubility in water and low toxicity but also peroxidase function and radical trapping function. Also, they found that the said compounds have effective antioxidant activity for the treatment and prevention of cell death of brain cells while showing low toxicity. As a result, the said compounds could be potential drug candidates for the treatment and prevention of cell death of brain cells.

The first object of the present invention is, therefore, to provide new type of antioxidants which are GPx mimics containing spin trapping moiety.

The second object of the invention is to provide a process for preparing the said antioxidants.

The third object of the invention is to provide pharmaceutical compositions comprising the said antioxidants as an active ingredient for the treatment and prevention of medical dysfunctions and diseases such as stroke, Parkinson's disease, and Alzheimer's disease caused by reactive oxygen species.

The fourth object of the invention is to provide a method for treating a living body afflicted with a condition requiring an antioxidant agent, in particular acute and progressive neurodegenerative disorders, by way of administering to the living body the said pharmaceutical preparations.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The above and the other objects and features of the present invention will become apparent from the following descriptions given in conjunction with the accompanying drawings, in which:

Fig.1 is a graph showing the results of combined treatment of Ebselen and  $Fe^{2+}$  toxin.

Fig.2 is a graph showing the results of combined treatment of compound obtained in Example 1 and  $Fe^{2+}$  toxin.

Fig.3 is a graph showing the results of combined treatment of compound obtained in Example 2 and  $Fe^{2+}$  toxin.

Fig.4 is a graph showing the results of combined treatment of compound obtained in Example 5 and  $Fe^{2+}$  toxin.

Fig.5 is a graph showing the results of combined treatment of compound obtained in Example 7 and  $Fe^{2+}$  toxin.

Fig.6 is a graph showing the level of cell damage as the treatment concentration of Ebselen increases.

Fig.7 is a graph showing the level of cell damage as the treatment concentration of compound obtained in Example 1 increases.

Fig.8 is a graph showing the level of cell damage as the treatment concentration of compound obtained in Example 2 increases.

Fig.9 is a graph showing the level of cell damage as the treatment concentration of compound obtained in Example 5 increases.

Fig.10 is a graph showing the level of cell damage as the treatment concentration of compound obtained in


Example 7 increases.

Fig.11-a is a graph showing the protection level of cell damage in case of the treatment of the compound of the invention after ischemia.

Fig.11-b is a photomicrograph showing the protection level of cell damage in case of the treatment of the compound of the invention after ischemia.

#### DETAILED DESCRIPTION OF THE INVENTION

In the first aspect, the present invention provides novel antioxidants with the following general formula (I), which have both peroxidase activity and free radical trapping activity as a dual function:



wherein,

$R_1$  and  $R_2$  which may be the same or different from each other, represent hydrogen, halogen,  $C_{1-4}$ -alkyl,  $C_{1-4}$ -alkoxy, hydroxy, trifluoromethyl, nitro, or  $R_3$  and  $R_3$  together denote methylenedioxy;

L denotes phenyl,  $C_{1-4}$ -alkylphenyl, heterocyclic unsaturated or saturated radical having 1 to 4 heteroatoms of elements nitrogen, oxygen, and/or sulfur from the group comprising furanyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl, benzimidazolyl, benzotriazolyl, triazinyl, triazolyl, it being possible for the heterocyclic radical to be substituted once or twice, identically or differently, by halogen,  $C_{1-4}$ -alkyl,  $C_{1-4}$ -alkoxy,  $C_{1-4}$ -alkylthio, hydroxy, mercapto, trifluoromethyl, nitro, phenyl, nitrile, carboxy or  $C_{1-4}$ -alkoxycarbonyl; and,

$R_3$  represents alkyl, substituted alkyl, alkenyl, alkynyl, aralkyl, aryl, cycloalkyl or cycloalkenyl.

In this context, preferred compounds include derivatives in which

$R_1$  and  $R_2$  can be identical or different and, independently of one another, denote hydrogen, fluorine, chlorine, bromine, hydroxy, methyl, ethyl, methoxy, trifluoromethyl, nitro or methylenedioxy;

$R_3$  denotes alkyl, substituted alkyl, aralkyl, aryl, and cycloalkyl; and,

L denotes phenyl, methylphenyl, ethylphenyl, heterocyclic unsaturated or saturated radical having 1 to 4 heteroatoms of the elements nitrogen, oxygen, and/or sulfur from the group comprising the furanyl, oxazolyl, thiophenyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl, triazinyl, triazolyl, it being possible for the heterocyclic radical to be substituted once or twice, identically or differently, by fluorine, chlorine, bromine, methyl, ethyl, butyl, methoxy, ethoxy, methylmercapto, ethylmercapto, hydroxy, mercapto, trifluoromethyl, nitro, phenyl, nitrile, carboxy or methoxycarbonyl and ethoxycarbonyl.

More preferred compounds include derivatives in which

$R_1$  and  $R_2$  can be identical or different and, independently of one another, denote hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, nitro or methylenedioxy;


L denotes phenyl, methylphenyl, ethylphenyl, heterocyclic unsaturated or saturated radical having 1 to 4 heteroatoms of the elements nitrogen, oxygen, and/or sulfur from the group comprising the furanyl, oxazolyl, thiophenyl, thiazolyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, benzothiazolyl, it being possible for the heterocyclic radical to be substituted once or twice,

identically or differently, by fluorine, chlorine, bromine, methyl, methoxy, ethoxy, methylmercapto, hydroxy, mercapto, nitro, phenyl, nitrile, carboxy or methoxycarbonyl and ethoxycarbonyl; and,

$R_3$  denotes alkyl, cycloalkyl.

The compounds of the invention possess similar or superior lipid peroxidation (LPO) inhibition activity to the reference compounds of S-PBN and Ebselen. While showing lower toxicity and better water solubility, they also effectively inhibit the cerebral neuronal cell death caused by ROS and show neuroprotective effects against ischemic neuronal degeneration.

The compounds of the invention, particularly the compound synthesized in Example 5 below, have a very low toxicity  $LD_{50}$   $\geq$  7,000 mg/kg in the case of oral administration in rats, and  $\geq$  800 mg/kg in the case of intraperitoneal administration in rats. Therefore, one of the advantages of the present invention is that the novel compounds can be administered at vastly higher levels than certain other known antioxidants, such as Ebselen ( $LD_{50}$  values of Ebselen obtained in mice were  $\geq$  6,810 mg/kg in the case of oral administration, and 740 mg/kg in the case of intraperitoneal administration. Similarly, the  $LD_{50}$  values of Ebselen obtained in rats were  $\geq$  6,810 mg/kg in the case of oral administration, and 580 mg/kg in the case of intraperitoneal administration). Accordingly, large doses of the novel compounds may be administered immediately post stroke or other traumas to reduce oxidative damage significantly.



In the second aspect, the present invention provides a process for the preparation of the compounds of formula (I) above, which is illustrated in the following reaction scheme:

N-protected aldehydes having proper linkers (L), represented as "1", react with alkylhydroxylamines ( $R_2NH_2$ ) to give nitrones shown as "2", which then undergo deprotection step to produce free amine nitrones represented as "3". Preferably, the alkylhydroxylamines are generated in situ from nitrosalkanes, zinc, and acetic acid. Removal of the protection group is carried out preferably with trifluoroacetic acid in case the protection group is tert-butoxycarbonyl, or LiOH in case the protection group is acetyl.

Free amines of the compound shown as "3" react with o-chloroselenobenzoyl chlorides (represented as "4") in the presence of excess base, organic base, more preferably triethylamine, to generate seleno compounds containing nitron moiety of formula (I).

In the third aspect, the present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount

of a compound of formula (I) above or pharmaceutically acceptable salts thereof.

In the fourth aspect, the present invention provides a method for treating a living body afflicted with a condition requiring an antioxidant, in particular acute and progressive neurodegenerative disorders, comprising a step of administering to the living body said pharmaceutical composition.

As previously mentioned, the compounds of the present invention have been proved to be effective antioxidants relieving various effects resulting from ROS. These compounds are useful as therapeutics for treating and/or preventing a wide variety of medical dysfunctions and diseases including, but not limited to, acute central nervous system (CNS) disorders and neurodegenerative diseases.

The compounds of the invention as pharmaceuticals, are typically administered in the form of a pharmaceutical composition comprising at least one active compound of the invention and a pharmaceutically acceptable carrier or vehicle suitable for use in pharmaceutical compositions.

In general, the compounds of the invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in light of relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. The dosage used ranges from 10 mg to 500 mg in one or several administrations per day.

The pharmaceutical compositions of the invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Depending on the intended

route of delivery, the compounds of this invention are preferably formulated as either injectable or oral compositions.

The compositions for oral administration can take the form of bulk liquid dilutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the seleno compounds containing nitron moiety of the invention is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or


other injectable carriers known in the art. As before, the present compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.

The components for orally administrable or injectable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pa., which is incorporated herein by reference.

The compounds of the invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in the incorporated materials in Remington's Pharmaceutical Sciences.

The following examples are provided to illustrate this invention and are not to be construed in any way as limiting the scope of this invention.

**Example 1:** Synthesis of 2-[4-(N-isopropyl)nitronyl]phenyl-1,2-benzisoxaselenazol-3(2H)-one (8)



**Step 1: Synthesis of 4-N-(1,1-dimethylethoxycarbonyl)aminobenzonitrile (2)**

500 mg (4.23 mmol) of 4-aminobenzonitrile (1) and 1.90 g (8.70 mmol) of di-tert-butyl dicarbonate (Boc<sub>2</sub>O) were added into a flask and the mixture was heated for 6 hours at 110 °C. The reaction mixture was cooled to room temperature and purified by short flash column chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>:Hex:EtOAc = 10:10:1) to give 630 mg (2.90 mmol) of compound 2 as a white solid in 68% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.58 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 2H), 6.65 (br s, 1H), 1.53 (s, 9H).

**Step 2: Synthesis of 4-N-(1,1-dimethylethoxycarbonyl)aminobenzaldehyde (3)**

To a solution of 600 mg (2.75 mmol) of nitrile 2 in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) were added 8.3 mL (8.3 mmol) of diisobutylaluminum hydride (DIBAL-H, 1.0 M soln in toluene) for 2 minutes at -78 °C. After stirring for 1 hour at that temperature, 2 mL of MeOH was slowly added to the reaction mixture, and then the reaction mixture was warmed to room temperature. Diethyl ether and 0.5 M HCl solution were added and the organic layer was separated. The aqueous layer was re-extracted with diethyl ether. The combined organic layers were washed with saturated NaHCO<sub>3</sub> solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>:Hex:EtOAc = 10:10:1 to 10:10:2) to give 585 mg (2.64 mmol) of compound 3 as a white solid in 96% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 9.89 (s, 1H), 7.83 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 6.70 (br

purified by short flash column chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>:EtOAc:MeOH = 5:5:1) to give 132 mg (0.74 mmol) of compound 6 as a yellow solid in 64% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.12 (d, J = 7.0 Hz, 2H), 7.27 (s, 1H), 6.68 (d, J = 7.0 Hz, 2H), 4.19 (septet, J = 6.5 Hz, 1H), 1.51 (d, J = 6.5 Hz, 6H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 149.08, 132.69, 131.04, 121.39, 114.66, 67.13, 21.23.

**Step 5: Synthesis of 2-[4-(N-isopropyl)nitronyl]phenyl-1,2-benzisoxaselenazol-3(2H)-one (8)**

To a solution of 75 mg (0.42 mmol) of compound 6 and 1.0 mL (7.17 mmol) of triethylamine in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was slowly added 200 mg (0.79 mmol) of 2-chlorocarbonyl-benzeneselenenyl chloride (7) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at 0 °C. After stirring for 4 hours at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>:EtOAc = 3:1 with 0 to 10% methanol) to give 83 mg (0.23 mmol) of compound 8 as a pale yellow solid in 55% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>:CD<sub>3</sub>OD = 4:1): δ 8.33 (d, J = 8.8 Hz, 2H), 8.08 (dd, J = 7.8 and 0.7 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.77 (dd, J = 8.8 and 1.9 Hz, 2H), 7.75 (t, J = 7.8 Hz, 1H), 7.60 (s, 1H), 7.48 (t, J = 7.8 Hz, 1H), 7.39 (s, 1H), 4.28 (septet, J = 6.5 Hz, 1H), 1.52 (d, J = 6.5 Hz, 6H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>:CD<sub>3</sub>OD = 4:1): δ 166.30, 141.11, 138.27, 133.14, 132.67, 129.92, 128.78, 127.86,

s, 1H), 1.55 (s, 9H).

**Step 3: Synthesis of N-isopropyl-α-(4-N-(1,1-dimethylethoxycarbonylamino)phenyl)nitron (5)**

422 mg (1.90 mmol) of compound 3, 680 mg (7.63 mmol) of 2-nitropropane (4), and 745 mg (11.40 mmol) of zinc were placed in a round-bottomed flask along with 95 % ethanol (8 mL). The mixture was cooled to 0 °C and 0.87 mL (15.20 mmol) of acetic acid was added slowly with stirring. The solution was allowed to come to room temperature, stirred for 6 hours. CH<sub>2</sub>Cl<sub>2</sub> was added to the reaction mixture and it was filtered through a Celite pad and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>:EtOAc = 1:2) to give 500 mg (1.80 mmol) of compound 5 as a white solid in 95% yield.


<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.21 (d, J = 8.9 Hz, 2H), 7.42 (d, J = 8.9 Hz, 2H), 7.37 (s, 1H), 6.61 (br s, 1H), 4.19 (septet, J = 6.5 Hz, 1H), 1.52 (s, 9H), 1.50 (d, J = 6.5 Hz, 6H).

**Step 4: Synthesis of N-isopropyl-α-(4-aminophenyl)nitron (6)**

To a solution of 320 mg (1.15 mmol) of compound 5 in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added 1 mL of trifluoroacetic acid slowly at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 hours. After concentration of the solution, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub> solution. The solution was saturated with NaCl and the organic layer was separated. The aqueous layer was extracted three times with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was

127.67, 126.40, 124.37, 124.21, 67.66, 20.44.

**Example 2: Synthesis of 2-[3-(N-isopropyl)nitronyl]phenyl-1,2-benzisoxaselenazol-3(2H)-one (15)**



**Step 1: Synthesis of ethyl 3-N-(1,1-dimethylethoxycarbonyl)aminobenzoate (10)**

To a solution of 5.0 g (30.27 mmol) of ethyl 3-aminobenzoate (9) and 17 mL (0.12 mol) of triethylamine in 150 mL of 1,4-dioxane/H<sub>2</sub>O (1:1 v/v) was added 16.32 g (75.67 mmol) of di-tert-butyl dicarbonate (Boc<sub>2</sub>O). After stirring for 13 hours at room temperature, H<sub>2</sub>O and diethyl ether were added. The organic layer was separated, washed with saturated NaCl solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by washing with n-hexanes to give 7.83 g (29.5 mmol) of compound 10 as a white solid in 98% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.90 (t, J = 1.7 Hz, 1H), 7.71 (m, 2H), 7.36 (t, J = 7.9 Hz, 1H), 6.63 (br s, 1H), 4.37 (m, 2H), 1.52 (s, 9H), 1.38

(t, J = 7.1 Hz, 3H).

**Step 2: Synthesis of 3-N-(1,1-dimethyl-ethoxycarbonyl)aminobenzyl alcohol (11)**

To a solution of 9.64 g (35.34 mmol) of ethyl benzoate 10 in  $\text{CH}_2\text{Cl}_2$  (200 mL) were added 109 mL of diisobutylaluminum hydride (DIBAL-H, 1.0 M soln in toluene) for 30 minutes at  $-78^\circ\text{C}$ . After stirring for 3 hours at that temperature, 30 mL of MeOH was added slowly to the reaction mixture, and then the reaction mixture was warmed to room temperature. Diethyl ether and 0.5 M HCl solution were added and the organic layer was separated. The solution was re-extracted with diethyl ether. The combined organic layers were washed with saturated  $\text{NaHCO}_3$  solution, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica,  $\text{CH}_2\text{Cl}_2$ :Hex:EtOAc = 10:10:1 to 10:10:2) to give 7.2 g (32.3 mmol) of compound 11 in 89% yield.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  7.42 (s, 1H), 7.24 (m, 2H), 7.0 (t, J = 6.9 Hz, 1H), 6.56 (s, 1H), 4.64 (s, 2H), 1.53 (s, 9H).

**Step 3: Synthesis of 3-N-(1,1-dimethylethoxycarbonyl)aminobenzaldehyde (12)**

To a solution of 5.63 mL (64.50 mmol) of oxalyl chloride in  $\text{CH}_2\text{Cl}_2$  (60 mL) was slowly added a solution of 6.92 mL (96.74 mmol) of DMSO in  $\text{CH}_2\text{Cl}_2$  (60 mL) at  $-78^\circ\text{C}$ . After 10 minutes, a solution of 7.2 g (32.3 mmol) of compound 11 in  $\text{CH}_2\text{Cl}_2$  (60 mL) was added slowly and the reaction mixture was stirred for 30 minutes. 34 mL of TEA was added slowly. The reaction mixture was warmed to room temperature.  $\text{CH}_2\text{Cl}_2$  and water were added and organic layer was separated. The organic layer was washed with saturated

slowly at  $0^\circ\text{C}$ . The reaction mixture was warmed to room temperature and stirred for 16 hours. After concentration of the solution, the mixture was diluted with  $\text{CH}_2\text{Cl}_2$  and saturated  $\text{NaHCO}_3$  solution. The solution was saturated with NaCl and the organic layer was separated. The aqueous layer was extracted three times with  $\text{CH}_2\text{Cl}_2$ . The combined organic layers were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica,  $\text{CH}_2\text{Cl}_2$ :EtOAc:MeOH = 5:5:1) to give 2.1 g (11.78 mmol) of compound 14 (mp: 103-106  $^\circ\text{C}$ ) as a yellow solid in 66% yield.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  8.12 (t, 1H), 7.30 (s, 1H), 7.16 (d, 2H), 6.74 (m, 1H), 4.18 (septet, J = 6.5 Hz, 1H), 3.74 (br s, 2H), 1.49 (d, J = 6.5 Hz, 6H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  147.11, 132.80, 131.88, 129.52, 119.87, 117.38, 114.77, 60.10, 21.24.

**Step 5: Synthesis of 2-[3-(N-isopropyl)nitronyl]phenyl-1,2-benziselenazol-3(2H)-one (15)**

To a solution of 50 mg (0.28 mmol) of compound 14 and 0.8 mL (5.62 mmol) of triethylamine in  $\text{CH}_2\text{Cl}_2$  (3 mL) was slowly added 178 mg (0.70 mmol) of 2-chlorocarbonylbenzeneselenenyl chloride (7) in  $\text{CH}_2\text{Cl}_2$  (1.5 mL) at  $0^\circ\text{C}$ . After stirring for 4 hours at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica,  $\text{CH}_2\text{Cl}_2$ :EtOAc = 3:1 with 0 to 10% methanol) to give 60 mg (0.17 mmol) of compound 15 (mp: 94-98 $^\circ\text{C}$ ) as a pale yellow solid in 60% yield.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  8.65 (m, 1H), 8.09 (m, 2H), 7.01 (d, 1H), 7.66 (m, 2H), 7.37 (m, 3H), 4.23

NaCl solution, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The resulting solid was washed with n-hexane to give 6.55 g (29.60 mmol) of compound 12 as a white solid in 92% yield.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  9.99 (t, J = 3.4 Hz, 1H), 7.92 (t, 1H), 7.64 (d, 1H), 7.62 (d, 1H), 7.45 (t, 1H), 6.70 (s, 1H), 1.55 (s, 9H).

**Step 4: Synthesis of N-isopropyl- $\alpha$ -(3-N-(1,1-dimethylethoxycarbonyl)amino)phenyl nitronyl (13)**

6.55 g (29.6 mmol) of compound 12, 6.65 mL (74.03 mmol) of 2-nitropropane (4), and 6.78 g (103.65 mmol) of zinc were placed in a round-bottomed flask along with 95 mL ethanol (100 mL) and cooled to  $0^\circ\text{C}$ . 11.9 mL (207.9 mmol) of acetic acid was added slowly with stirring. The solution was allowed to come to room temperature, stirred for 12 hours.  $\text{CH}_2\text{Cl}_2$  was added to the reaction mixture and it was filtered through a Celite pad and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica,  $\text{CH}_2\text{Cl}_2$ :EtOAc = 1:2) to give 7.0 g (21.3 mmol) of compound 13 (mp: 189-191  $^\circ\text{C}$ ) in 72% yield.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  8.37 (s, 1H), 7.8 (d, J = 7.7 Hz, 1H), 7.5 (d, J = 7.7 Hz, 1H), 7.42 (s, 1H), 7.33 (t, J = 7.8 Hz, 1H), 6.60 (s, 1H), 4.19 (septet, J = 6.5 Hz, 1H), 1.53 (s, 9H), 1.48 (d, J = 6.5 Hz, 6H).


**Step 5: Synthesis of N-isopropyl- $\alpha$ -3-aminophenyl nitronyl (14)**

To a solution of 5.0 g (17.96 mmol) of compound 13 in  $\text{CH}_2\text{Cl}_2$  (200 mL) was added 20 mL of trifluoroacetic acid

(septet, J = 6.5 Hz, 1H), 1.52 (d, J = 6.5 Hz, 6H);

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  166.23, 139.77, 138.18, 133.00, 132.21, 131.79, 129.69, 127.95, 127.12, 126.96, 126.90, 125.17, 124.30, 68.53, 67.48, 21.33.

**Example 1: Synthesis of 5-chloro-2-[3-(N-isopropyl)nitronyl]phenyl-1,2-benziselenazol-3(2H)-one (17)**




A similar procedure as that described for compound 8 in Example 1 provided 40 mg (0.10 mmol) of compound 17 as a yellow solid in 18% yield from 290 mg (1.01 mmol) of 4-chloro-2-chlorocarbonylbenzeneselenenyl chloride (16) and 100 mg (0.56 mmol) of N-isopropyl- $\alpha$ -3-aminophenyl nitronyl (14).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ : $\text{CD}_3\text{OD}$  = 4:1):  $\delta$  8.63 (t, J = 1.7 Hz, 1H), 8.02 (d, J = 2.2 Hz, 1H), 8.00 (d, J = 7.9 Hz, 1H), 7.81 (dd, J = 7.9 and 2.3 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H), 7.61 (dd, J = 8.5 and 2.3 Hz, 1H), 7.53 (t, J = 7.9 Hz, 1H), 4.28 (septet, J = 6.5 Hz, 1H), 1.50 (d, J = 6.5 Hz, 6H);

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ : $\text{CD}_3\text{OD}$  = 4:1):  $\delta$  166.30, 141.11, 138.27, 133.14, 132.67, 129.92, 129.77, 127.86, 127.67, 126.45, 124.37, 124.21, 67.66, 20.44.

**Example 4:** Synthesis of 5-methyl-2-[3-(N-isopropyl)nitronyl]phenyl-1,2-benziselenazol-3(2H)-one (19)



A similar procedure as that described for compound 8 in Example 1 provided 40 mg (0.20 mmol) of compound 19 (mp: 197-201 °C) as yellow solid in 30% yield from 380 mg (1.40 mmol) of 4-methyl-2-chlorocarbonylbenzeneselenenyl chloride (18) and 100 mg (0.56 mmol) of N-isopropyl-α-3-aminophenylnitron (14).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.60 (s, 1H), 8.09 (d, J = 7.7 Hz, 1H), 7.90 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.44 (m, 3H), 4.23 (septet, J = 6.5 Hz, 1H), 2.47 (s, 3H), 1.51 (d, J = 6.5 Hz, 6H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 166.25, 139.91, 137.07, 134.76, 134.39, 132.19, 131.78, 129.73, 129.71, 127.94, 127.09, 126.85, 125.14, 123.96, 68.51, 60.79, 21.41, 14.59.

**Example 5:** Synthesis of 2-[4-(N-isopropyl)nitronyl]thiazol-2-yl-1,2-benziselenazol-3(2H)-one (26)

(from ester 21)

To a solution of 7.0 g (25.71 mmol) of ethyl ester 21 in CH<sub>2</sub>Cl<sub>2</sub> (75 mL) were added 77 mL of diisobutylaluminum hydride (DIBAL-H, 1.0 M soln in toluene) for 20 minutes at -78 °C. After stirring for 3 hours at that temperature, 30 mL of MeOH was added slowly to the reaction mixture, and then the reaction mixture was warmed to room temperature. Diethyl ether and 0.5 N HCl solution were added and the organic layer was separated. The solution was re-extracted with diethyl ether. The combined organic layers were washed with saturated NaHCO<sub>3</sub> solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>:Hex:EtOAc = 10:6:3 to CH<sub>2</sub>Cl<sub>2</sub>:EtOAc = 1:1) to give 1.90 g (0.32 mmol) of solid aldehyde 22 in 32.4% yield and 3.5 g (15.20 mmol) of liquid alcohol 23 in 59.0% yield.

Aldehyde 22:


<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 9.88 (s, 1H), 8.83 (br s, 1H), 8.82 (s, 1H), 1.58 (s, 9H).

Alcohol 23:

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 6.75 (s, 1H), 4.58 (s, 2H), 1.58 (s, 9H)

**Step 2-1:** Synthesis of 2-N-(1,1-dimethylethoxy-carbonyl)aminothiazole-4-carbaldehyde (22) (from alcohol 23)

To a solution of 2.04 g (0.597 mmol) of alcohol 23 in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) were added 302 mg (0.86 mmol) of TPAP (tetrapropylammonium perruthenate), 3.11 g (26.547 mmol) of NMO (N-methylmorpholine N-oxide) and 16 g (2 g/l mmol of alcohol) of 4 Å molecular sieve. After stirring for 2



**Step 1:** Synthesis of ethyl 2-N-(1,1-dimethylethoxy-carbonyl)aminothiazole-4-carboxylate (21)

6.05 g (35.13 mmol) of aminothiazole 20 and 26.84 g (0.12 mmol) of di-tert-butyl dicarbonate (Boc<sub>2</sub>O) were added into a flask and the mixture was heated for 24 hours at 110 °C. The reaction mixture was cooled to room temperature and purified by short flash column chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>:Hex:EtOAc = 10:6:3) to give 7.13g (26.18 mmol) of compound 21 as a white solid in 74.5% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.21 (br s, 1H), 7.78 (s, 1H), 4.38 (q, J = 7.1 Hz, 2H), 1.54 (s, J = 7.1 Hz, 9H), 1.38 (t, 3H).

**Step 2:** Synthesis of 2-N-(1,1-dimethylethoxy-carbonyl)aminothiazole-4-carbaldehyde (22)

hours at room temperature, the reaction mixture was filtered through a Celite pad and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica, CH<sub>2</sub>Cl<sub>2</sub>:Hex:EtOAc = 10:6:3) to give 950 mg (4.0 mmol) of aldehyde 22 in 46.5% yield.

**Step 3:** Synthesis of N-isopropyl-α-(2-N-(1,1-dimethylethoxycarbonyl)aminothiazol-4-yl)nitron (24)

2.22 g (9.72 mmol) of compound 22, 3.47g (33.65 mmol) of 2-nitropropane (4), and 2.54 g (38.84 mmol) of zinc were placed in a round-bottomed flask along with 95 % ethanol (50 mL) and cooled to 0 °C. 4.67 g (77.77 mmol) of acetic acid was added slowly with stirring. The solution was allowed to come to room temperature, stirred for 6 hours. CH<sub>2</sub>Cl<sub>2</sub> was added to the reaction mixture and it was filtered through a Celite pad and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, Hex:EtOAc = 1:1) to give 2.51 g (8.80 mmol) of compound 24 in 90.5% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.71 (s, 1H), 7.63 (s, 1H), 4.21 (septet, J = 6.6 Hz, 1H), 1.55 (s, 9H), 1.49 (d, J = 6.6 Hz, 6H).

**Step 4:** Synthesis of N-isopropyl-α-(2-aminothiazol-4-yl)nitron (25)

To a solution of 2.44 g (8.55 mmol) of compound 24 in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added 3.3 mL of trifluoroacetic acid slowly at 0 °C. The reaction mixture was warmed to room temperature and stirred for 16 hours. After concentration of the solution, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub> solution. The solution was saturated with NaCl and the organic layer was separated. The aqueous layer was extracted three times with CH<sub>2</sub>Cl<sub>2</sub>. The combined

organic layers were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica,  $\text{CH}_2\text{Cl}_2:\text{EtOAc}:\text{MeOH} = 5:5:1$ ) to give 1.6 g (8.46 mmol) of compound 25 as a yellow solid in 99% yield.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  8.38 (s, 1H), 7.59 (s, 1H), 5.61 (b, 2H), 4.16 (septet,  $J = 6.5$  Hz, 1H), 1.46 (d,  $J = 6.5$  Hz, 6H).

**Step 5: Synthesis of 2-[4-(N-isopropyl)nitronyl]thiazol-2-yl-1,2-benzisoselesenzol-3(2H)-one (26)**

To a solution of 100 mg (0.53 mmol) of compound 25 and 0.74 mL (5.29 mmol) of triethylamine in  $\text{CH}_2\text{Cl}_2$  (15 mL) was slowly added 220 mg (0.866 mmol) of 2-chlorocarbonyl-benzene-selenenyl chloride (7) in  $\text{CH}_2\text{Cl}_2$  (5 mL) at 0 °C. After stirring for 1 hour at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by recrystallization (MeOH/ $\text{CH}_2\text{Cl}_2$ ) to give 70 mg (0.19 mmol) of compound 26 as a pale yellow solid in 37% yield.

$^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  8.82 (s, 1H), 8.15 (s, 1H), 8.05 (d,  $J = 7.8$  Hz, 1H), 8.03 (d,  $J = 8.0$  Hz, 1H), 7.75 (t,  $J = 7.3$  Hz, 1H), 7.53 (t,  $J = 7.4$  Hz, 1H), 4.43 (septet,  $J = 6.8$  Hz, 1H), 1.50 (d,  $J = 6.8$  Hz, 6H).

**Example 6: Synthesis of 2-[4-(N-tert-butyl)nitronyl]thiazol-2-yl-1,2-benzisoselesenzol-3(2H)-one**

To a solution of 200 mg (0.668 mmol) of compound 28 in  $\text{CH}_2\text{Cl}_2$  (10 mL) was added 381 mg of trifluoroacetic acid slowly at 0 °C. The reaction mixture was warmed to room temperature and stirred for 14 hours. After concentration of the solution, the mixture was diluted with  $\text{CH}_2\text{Cl}_2$  and saturated  $\text{NaHCO}_3$  solution. The solution was saturated with NaCl and the organic layer was separated. The aqueous layer was extracted three times with  $\text{CH}_2\text{Cl}_2$ . The combined organic layers were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, EtOAc) to give 111 mg (0.56 mmol) of compound 29 as a yellow solid in 83% yield.


$^1\text{H}$  NMR (MeOD):  $\delta$  8.29 (s, 1H), 7.82 (s, 1H), 4.91 (s, 2H), 1.54 (s, 9H).

$^{13}\text{C}$  NMR (MeOD):  $\delta$  168.76, 141.94, 127.57, 114.24, 70.23, 27.20.

**Step 3: Synthesis of 2-[4-(N-tert-butyl)nitronyl]thiazol-2-yl-1,2-benzisoselesenzol-3(2H)-one (30)**

To a solution of 100 mg (0.50 mmol) of compound 29 and 0.70 mL (5.02 mmol) of triethylamine in  $\text{CH}_2\text{Cl}_2$  (15 mL) was slowly added 180 mg (0.703 mmol) of 2-chlorocarbonyl-benzene-selenenyl chloride (7) in  $\text{CH}_2\text{Cl}_2$  (5 mL) at 0 °C. After stirring for 1 hour at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, EtOAc:Hex = 1:1) to give 67 mg (0.176 mmol) of compound 30 as a pale yellow solid in 35% yield.

$^1\text{H}$  NMR ( $\text{CDCl}_3:\text{CD}_3\text{OD} = 10:1$ ):  $\delta$  8.80 (s, 1H), 8.04 (d,



**Step 1: Synthesis of N-tert-butyl- $\alpha$ -(2-N-(1,1-dimethylethoxycarbonyl)aminothiazol-4-yl)nitron (28)**

2.0 g (8.76 mmol) of compound 22, 5.42 g (52.57 mmol) of 2-methyl-2-nitropropane (27), and 2.86 g (43.81 mmol) of zinc were placed in a round-bottomed flask along with 95 mL ethanol (50 mL) and cooled to 0 °C. 4.21 g (70.11 mmol) of acetic acid was added slowly with stirring. The solution was allowed to warm to room temperature, stirred for 6 hours.  $\text{CH}_2\text{Cl}_2$  was added to the reaction mixture and it was filtered through a Celite pad and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, Hex:EtOAc = 1:1) to give 1.28 g (4.28 mmol) of compound 28 as a yellow solid in 49% yield.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  9.9 (br s, 1H), 8.82 (s, 1H), 7.87 (s, 1H), 1.60 (s, 9H), 1.54 (s, 6H).


$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  139.54, 152.35, 141.53, 125.78, 117.31, 82.83, 70.33, 28.27, 28.21.

**Step 2: Synthesis of N-tert-butyl- $\alpha$ -(2-aminothiazol-4-yl)nitron (29)**

$J = 7.6$  Hz, 1H), 7.91 (s, 1H), 7.60 (d,  $J = 7.86$  Hz, 1H), 7.61 (t,  $J = 7.2$  Hz, 1H), 7.40 (t,  $J = 7.41$  Hz, 1H), 1.56 (s, 9H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3:\text{CD}_3\text{OD} = 10:1$ ):  $\delta$  165.38, 157.10, 140.74, 139.19, 133.71, 128.76, 127.05, 126.78, 124.72, 119.43, 70.54, 28.05.

**Example 7: Synthesis of 2-[4-(N-isopropyl)nitronyl]benzyl-1,2-benzisoselesenzol-3(2H)-one (37)**



**Step 1: Synthesis of methyl 4-N-(1,1-dimethylethoxycarbonyl)aminomethylbenzoate (32)**

To a solution of 500 mg (2.48 mmol) of methyl 4-aminomethylbenzoate HCl salt (31) in  $\text{CH}_2\text{Cl}_2$  (10 mL) were added 753 mg (7.45 mmol) of TEA and 568 mg (2.60 mmol) of Boc-O in  $\text{CH}_2\text{Cl}_2$  (1 mL) at 0 °C. After 30 minutes, the reaction mixture was warmed to room temperature. After additional stirring for 4 hours,  $\text{CH}_2\text{Cl}_2$  was added to the reaction mixture. The organic layer was washed with 0.1 N HCl solution, dried over  $\text{MgSO}_4$ , filtered, and concentrated

under reduced pressure. The residue was purified by flash column chromatography (silica, Hex:EtOAc = 1:1) to give 620 mg of compound 32 in 94% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.58 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 4.90 (br s, 1H), 4.37 (d, 2H), 3.91 (s, 3 H), 1.46 (s, 9H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 167.02, 156.015, 144.042, 130.03, 129.23, 127.27, 79.91, 52.23, 44.43, 28.49

**Step 2:** Synthesis of 4-N-(1,1-dimethylethoxy-carbonyl) aminomethylbenzyl alcohol (33)

To a solution of 620 mg (2.34 mmol) of ethyl benzoate 32 in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added 7.01 mL of diisobutylaluminum hydride (DIBAL-H, 1.0 M soln in toluene) for 30 minutes at -78 °C. After stirring for 3 hours at that temperature, 3 mL of MeOH was added slowly to the reaction mixture, and then the reaction mixture was warmed to room temperature. Diethyl ether and 0.5 N HCl solution were added and the organic layer was separated. The solution was re-extracted with diethyl ether. The combined organic layers were washed with saturated NaHCO<sub>3</sub> solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, Hex:EtOAc = 2:1) to give 520 mg (2.19 mmol) of compound 33 in 94% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.32 (m, 4H), 4.80 (br s, 1H), 4.68 (s, 2H), 4.31 (m, 2H), 1.46 (s, 9H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.6, 140.19, 138.30, 127.69,

to come to room temperature, stirred for 6 hours. CH<sub>2</sub>Cl<sub>2</sub> was added to the reaction mixture and it was filtered through a Celite pad and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, Hex:EtOAc = 1:1) to give 540 mg (1.85 mmol) of compound 35 in 87% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.21 (d, J = 8.2 Hz, 2H), 7.42 (s, 1H), 7.32 (d, J = 8.2 Hz, 2H), 4.86 (br s, 1H), 4.33 (m, 2H), 4.23 (septet, J = 6.5 Hz, 1H), 1.50 (d, J = 6.5 Hz, 6H), 1.45 (s, 9H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.00, 141.33, 131.80, 129.62, 128.78, 127.28, 79.42, 67.64, 44.36, 28.37, 20.83

**Step 1:** Synthesis of N-isopropyl-α-(4-aminomethyl-phenyl)nitrozone (36)

To a solution of 200 mg (0.68 mmol) of compound 35 in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added 0.34 mL of trifluoroacetic acid slowly at 0 °C. The reaction mixture was warmed to room temperature and stirred for 6 hours. After concentration of the solution, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub> solution. The solution was saturated with NaCl and the organic layer was separated. The aqueous layer was extracted three times with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, EtOAc:MeOH = 9:1 to 4:1) to give 130 mg (0.68 mmol) of compound 36 as a yellow solid in 99% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.10 (d, J = 8.4 Hz, 2H), 7.45 (s, 1H), 7.34 (d, J = 8.4 Hz, 2H), 4.13

127.33, 79.67, 64.93, 44.44, 28.49

**Step 3:** Synthesis of 4-N-(1,1-dimethylethoxy-carbonyl)aminomethylbenzaldehyde (34)

To a solution of 0.48 mL (3.48 mmol) of oxalyl chloride in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was slowly added a solution of 0.63 mL (8.76 mmol) of DMSO in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at -78 °C. After 15 minutes, a solution of 520 mg (2.19 mmol) of compound 33 in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added slowly and the reaction mixture was stirred for 30 minutes. 2.5 mL of TEA was added slowly. The reaction mixture was warmed to room temperature. CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O were added and organic layer was separated. The organic layer was washed with saturated NaCl solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, Hex:EtOAc = 2:1) to give 510 mg (2.17 mmol) of compound 34 in 99% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 9.99 (s, 1H), 7.85 (d, J = 7.9 Hz, 2H), 7.44 (d, J = 7.9 Hz, 2H), 4.95 (br s, 1H), 4.40 (d, 2H), 1.47 (s, 9H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 191.95, 156.01, 146.37, 135.24, 129.93, 127.53, 79.57, 44.13, 28.28

**Step 4:** Synthesis of N-isopropyl-α-[4-N-(1,1-dimethylethoxycarbonylamino)methylphenyl]nitrozone (35)

500 mg (2.13 mmol) of compound 34, 0.44 mL (4.84 mmol) of 2-nitropropane (4), and 565 mg (8.64 mmol) of zinc were placed in a round-bottomed flask along with 95% ethanol (10 mL) and cooled to 0 °C. 0.83 mL of acetic acid was added slowly with stirring. The solution was allowed

(septet, J = 6.54 Hz, 1H), 3.88 (s, 2H), 1.41 (d, J = 6.54 Hz, 6H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 137.05, 135.89, 132.38, 130.98, 130.05, 68.80, 43.92, 20.90


**Step 6:** Synthesis of 2-[4-(N-isopropyl)-nitronyl]benzyl-1,2-benziselenazol-3(2H)-one (37)

To a solution of 80 mg (0.42 mmol) of compound 36 and 0.29 mL (2.08 mmol) of triethylamine in CH<sub>3</sub>CN (15 mL) and EtOH (1 mL) was slowly added 138 mg (0.54 mmol) of 2-chlorocarbonylbenzoeselenenyl chloride (7) in CH<sub>3</sub>CN (4 mL) at 0 °C. After stirring for 4 hours at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, EtOAc) to give 70 mg (0.19 mmol) of compound 37 as a pale yellow solid in 45% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.24 (d, J = 8.1 Hz, 2H), 8.04 (d, J = 7.9 Hz, 1H), 7.91 (s, 1H), 7.87 (d, J = 6.4 Hz, 1H), 7.63 (d, J = 6.8 Hz, 1H), 7.45 (t, J = 6.9 Hz, 1H), 7.37 (d, J = 8.1 Hz, 2H), 4.95 (s, 2H), 4.34 (septet, J = 6.3 Hz, 1H), 1.36 (d, J = 6.3 Hz, 6H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 140.12, 139.24, 131.99, 130.73, 129.20, 128.66, 128.06, 126.29, 125.79, 68.09, 48.21, 21.021

**Example 8:** Synthesis of 7-Nitro-2-[4-(N-isopropyl)nitronyl] phenyl-1,2-benziselenazol-3(2H)-one (40)



**Step 1: Synthesis of 2-Methylseleno-3-nitrobenzoic acid (39)**

To a solution of 500 mg (2.0 mmol) of 2-bromo-3-nitrobenzoic acid in anhydrous THF (15 mL) was added 2.80 mL (4.47 mmol) of *n*-BuLi (1.6 M soln. in Hex.) slowly at -78 °C. After 10 minutes, a solution of 383 mg (2.03 mmol) of dimethyl diselenide in THF (5 mL) was added. After 30 minutes, the reaction mixture was warmed to room temperature. After additional stirring for 2 hours, ethyl acetate was added. The organic layer was washed with 1 N HCl solution, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. 470 mg of crude product was obtained and used for the next reaction without further purification.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.91 (d, J = 7.85 Hz, 1H), 7.88 (d, J = 7.85 Hz, 1H), 7.56 (t, J = 7.85 Hz, 1H), 2.31 (s, 3H).

**Step 2: Synthesis of 7-Nitro-2-[(4-N-isopropyl)-nitronyl]phenyl-1,2-benzisoseleazol-3(2H)-one (40)**

470 mg of crude product 39 was refluxed with 4 mL of

SOCl<sub>2</sub> for 4 hours. After removal of excess thionyl chloride, the crude product 39 was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). To a solution of 100 mg (0.56 mmol) of compound 14 and 0.568 mg (5.61 mmol) of triethylamine in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was slowly added 3 mL of compound 39 solution obtained in the above at 0 °C. After stirring for 2 hours at room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by short flash column chromatography (silica, EtOAc) to give 121 mg (0.30 mmol) of compound 40 in 53% yield.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.79 (s, 1H), 8.61 (d, J = 8.07 Hz, 1H), 8.49 (d, J = 7.56 Hz, 1H), 8.03 (d, J = 7.76 Hz, 1H), 7.87 (d, J = 8.10 Hz, 1H), 7.76 (t, J = 7.71 Hz, 1H), 7.55 (s, 2H), 4.28 (septet, J = 6.63 Hz, 1H), 1.56 (d, J = 6.51 Hz, 6H);

<sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 164.03, 142.11, 138.78, 136.52, 135.27, 132.16, 131.42, 131.25, 129.66, 127.95, 127.77, 127.08, 126.41, 124.16, 68.33, 21.05.

Using the procedures described in Examples 1-8 above and the appropriate starting materials and reagents, the following seleno compounds containing nitron moiety could be prepared:

- 2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 2-[2-(N-tert-butyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 5-fluoro-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 5-chloro-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 5-bromo-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-

- benzisoseleazol-3(2H)-one;
- 5-methyl-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 5-methoxy-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 6-chloro-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 6-methyl-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 5-nitro-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 7-nitro-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 6,7-methylenedioxy-2-[2-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 2-[3-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 2-[4-(N-isopropyl)nitronyl]-phenyl-1,2-benzisoseleazol-3(2H)-one;
- 2-[4-(N-isopropyl)nitronyl]-benzyl-1,2-benzisoseleazol-3(2H)-one;
- 2-[4-(N-isopropyl)nitronyl]-phenylethyl-1,2-benzisoseleazol-3(2H)-one;
- 2-[4-(N-isopropyl)nitronyl]-pyridin-2-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[5-(N-isopropyl)nitronyl]-pyridin-2-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[4-(N-isopropyl)nitronyl]-pyrimidin-2-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[5-(N-isopropyl)nitronyl]-pyrimidin-2-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[5-(N-isopropyl)nitronyl]-furan-2-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[5-(N-isopropyl)nitronyl]-thiophen-2-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[4-(N-isopropyl)nitronyl]-thiazol-2-yl-1,2-benzisoseleazol-3(2H)-one;

- 2-[4-(N-isopropyl)nitronyl]-oxazol-2-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[2-(N-isopropyl)nitronyl]-1H-imidazol-4-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[2-(N-isopropyl)nitronyl]-1-methyl-1H-imidazol-4-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[5-(N-isopropyl)nitronyl]-1H-pyrrol-3-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[5-(N-isopropyl)nitronyl]-1-methyl-1H-pyrrol-3-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[6-(N-isopropyl)nitronyl]-benzothiazol-2-yl-1,2-benzisoseleazol-3(2H)-one;
- 2-[5-(N-isopropyl)nitronyl]-2H-[1,2,4]-triazol-3-yl-1,2-benzisoseleazol-3(2H)-one; and,
- 2-[5-(N-isopropyl)nitronyl]-2-methyl-2H-[1,2,4]-triazol-3-yl-1,2-benzisoseleazol-3(2H)-one.

#### Example 3: Determination of Water Solubility

A standard solution was prepared by dissolving a precisely weighed amount (generally 1 mg) of the test compounds in 1 mL of methanol. With a Beckman DU® 7500 Spectrophotometer, the UV absorption maximum of each compound was determined by eventually diluting the solution with MeOH as necessary.

A saturated solution of each compound was then prepared by stirring magnetically a small volume of 10 mM phosphate buffer (pH 7.4) in the presence of an excess test compound for 3 hours. The obtained saturated solution was filtered in order to remove solid compound through a Gelman 0.45 µm filter and scanned by UV at the wavelength of the absorption maximum previously determined.

Total solubility was determined by the following equation:  $C' = A'(C/A)$ , where C = concentration of standard solution (mg/mL); A = absorbance of standard solution; A' = absorbance of the saturated solution; C' = concentration of the saturated solution (mg/mL) (see: Protein Sci., 7:

556-563, (1998)). The results are summarized in Table 1.

Table 1.

Compounds	Ebselen	Example 1	Example 2	Example 5	Example 7
Amount added (mg)	5.71	5.14	5.55	5.74	5.02
Wavelength (determined)	330nm	314	294	302	300
Measured Abs.	0.0284	0.6096	0.3584	0.1827	1.2276
Dilution factor	1	1	10	10	1
A'	0.0284	0.6096	3.584	1.827	1.2276
A	0.6154	1.6807	1.2729	0.8882	0.8871
C (μM)	100	50	50	50	50
C' (μM) = A' (C/A)	4.615	18.135	140.781	113.029	69.192
C'' (g/L = mg/mL)	0.001265	0.006316	0.050580	0.041403	0.025830

It can be clearly seen from the table 1 that the compounds of the present invention have much better water solubility than Ebselen has.

#### Example 10: Inhibition of lipid peroxidation

The compounds of the present invention were tested for antioxidant effect in terms of the repression of the radical chain reaction of a multilayer liposome.

The liposome was prepared as follows: 30 mg of commercially available soybean phosphatidylcholine (PC, Sigma Chemical Co., U.S.A.) was dissolved in 1 mL of ethanol, and 200 μL of the ethanol/PC solution was added to 10 mL of 10 mM Tris buffer including 50 mM NaCl (pH 7.0) with stirring.

The ability of a compound to inhibit oxidation of the liposome was evaluated as follows: To 400 μL of the

liposomes were added the test compound (in buffer or ethanol) and histidine-FeCl<sub>2</sub> (167:33 μM final). Oxidation was initiated by the addition of FeCl<sub>2</sub> (33 μM final prepared in nitrogen purged water). The mixtures were shaken at 37 °C for 15 minutes. Thereafter, tubes were treated with 1 mL of 0.67% thiobarbituric acid (TBA): 10% trichloroacetic acid (2:1, v/v) in 0.25 M HCl solution, containing 1.5% (v/v) t-butylhydroxytoluene (BHT) to terminate oxidation. The aliquots were heated to 100 °C for 20 minutes. After ice cooling, 1 mL of chloroform was added to 1 mL of supernatant from tubes and tubes were centrifuged. The absorbances of the resulting supernatant were measured at 532 nm (see: Table 2).

Table 2.

Inhibitor Concentration (IC <sub>50</sub> )	
Example 1	81.1 μM
Example 2	111.0 μM
Example 5	1.2 μM
Example 7	246.5 μM
S-PBN	25.0 mM
Ebselen	148.3 μM

It can be seen from the Table 2 that the compounds of the invention, especially the compound obtained in example 5 have better LPO inhibition activity than the reference compounds S-PBN and Ebselen (the most promising antioxidant currently and is in clinical phase III).

#### Example 11: Measurement of Glutathione Peroxidase Activity

Glutathione peroxidase like activity was determined by the reduction of GSSG formed via the NADPH-glutathione reductase system as an indicator system.

To 350 μL of 50 mM Tris-HCl (pH 7.6) containing 5 mM of EDTA (assay buffer) are added in the following order:

1) 350 μL of assay buffer containing 6.4 mM of reduced glutathione (GSH), 640 μM of nicotinamide adenine dinucleotide (NADPH), and 1.6 unit/mL of glutathione disulfide reductase (GR)

2) 70 μL of 800 μM of the test compound which was dissolved in DMSO (i.e., each compound was tested at a final concentration of 50 μM)

3) 350 μL of 0.007% tert-butyl hydroperoxide which was made by 1/10,000 dilution of tert-butyl hydroperoxide with DDW.

The final reaction volume is 1120 μL.

The reaction was carried out at 25 °C. The glutathione peroxidase activity is assayed by measuring the decrease of absorbance at 340 nm for 3 minutes. The said activity or initial enzymatic rate is proportional to the slope of the variation of absorbance with time.

The catalytic activity for oxygen reduction of the compounds tested corresponds to the rate of consumption of NADPH.

The results of the glutathione peroxidase activity measurements are shown in Table 3 below. They are expressed in n-moles of NADPH consumed per minute.

Table 3.

Compound	Rate (nmoles (30-360sec))	Rate/0.00622 (nmoles NADPH/min/mL)	% Ebselen
Ebselen	-0.118	18.97	100
Example 1	-0.101	22.67	119.50
Example 2	-0.125	20.10	105.96
Example 5	-0.125	20.13	106.11

Example 7	-0.084	13.50	71.17
-----------	--------	-------	-------

As shown in Table 3 above, the compounds of general formula (I) described in the invention catalyze the reduction of an organic hydroperoxide, in the presence of glutathione and glutathione disulfide reductase. Thus, it is noted that the compounds of the invention possess a significant and specific glutathione peroxidase activity.

#### Example 12: Protection of neuron cells

##### Example 12-1: The culture of neuron cells of cerebral Cortex

Mixed cortical cell cultures, containing both neuronal and glial elements, were prepared from fetal ICR (Institute Cancer Research) mice at 14-15 days of gestation. Briefly, dissociated cortical cells were plated onto previously established glial monolayer culture at 2.5 hemispheres per 24-multiwell plate (Nunc, U.S.A.). The plating medium consisted of Eagle's minimal essential medium (Earle's salts, supplied glutamine-free) supplemented with glucose (final concentration, 20 mM), 2 mM glutamine, 5% fetal bovine serum, and 5% horse serum. Ten mM cytosine arabinoside was added to the medium 5-6 days after the plating to halt the growth of non-neuronal cells. Cultures were maintained at 37 °C in a humidified CO<sub>2</sub> incubator (5%) and used for experiments after between 10-14 days in vitro (DIV).

The glial feeder cultures were prepared from neocortices of postnatal (1-3 day-old) mice. Dissociated cortical cells were plated at 0.25 hemispheres per 24-multiwell plate, in plating medium supplemented with 5% fetal bovine serum, and 10% horse serum. With this method, most neurons do not survive, but astrocytes do, resulting in astrocyte-rich cultures. Glial cultures were grown to confluency for 10-30 days, when they were used to

generate mixed cortical cultures.

**Example 12-2: Protection of cortical neuronal cell death induced by  $Fe^{2+}$  ion**

When ferrous iron is placed in normoxic solution, it autooxidizes to produce ROS in the form of hydroxyl radicals, superoxide anion free radicals, and hydrogen peroxide.

Cortical cell cultures prepared in Example 12-1 were exposed for 24 hours to 30  $\mu M$   $FeCl_2$  ( $Fe$ ), to induce neuronal cell death. 24 hours exposure to toxin with or without test compounds was done in serum free Eagle's minimal essential medium (MEM) supplemented with 20  $\mu M$  glucose and 38  $mM$  sodium bicarbonate in 5%  $CO_2$  incubator at 37  $^{\circ}C$ . All of compounds were dissolved in DMSO at high concentrations, and then diluted to final concentrations in the exposure medium at the time of addition.

Methods of measuring cell death were as follows:

Overall cell injury was first estimated in all experiments by examination of cultures under phase-contrast microscope. The morphological assessments were usually performed one day after exposure to toxins, at which point the process of cell death was largely completed.

In addition, overall neuronal cell injury was quantitatively estimated by measuring the activity of lactate dehydrogenase (LDH), released by damaged or destroyed cells, into the extracellular fluid. A small amount of LDH was always present in the media of cultures that underwent the same exposure procedures but without the addition of toxins (sham wash controls). This background amount, determined on sister sham wash controls within each experiment, was subtracted from values obtained in toxin-treated cultures. The absolute value of the LDH efflux produced by toxin exposure was quite consistent within sister cultures of single plating, but

varied somewhat in cultures of different platings. This variability is largely a function of resultant neuronal density (which varied despite constant original plating densities, presumably reflecting small variations in cell preparation or serum characteristics). Therefore, each LDH value was scaled to the maximal neuronal LDH release (= 100) after 24 hours exposure to 30  $\mu M$   $FeCl_2$  ( $Fe$ ), in sister cultures, where near complete neuronal death with no glial damage occurs. Numbers greater than 100 usually indicate additional astroglial cell injury.

Fig.1 is a graph showing the results of combined treatment of Ebbselen and  $Fe^{2+}$  toxin.

Fig.2 is a graph showing the results of combined treatment of compound obtained in Example 1 and  $Fe^{2+}$  toxin.

Fig.3 is a graph showing the results of combined treatment of compound obtained in Example 2 and  $Fe^{2+}$  toxin.

Fig.4 is a graph showing the results of combined treatment of compound obtained in Example 5 and  $Fe^{2+}$  toxin.

Fig.5 is a graph showing the results of combined treatment of compound obtained in Example 7 and  $Fe^{2+}$  toxin.

As can be seen in Figs. 1 to 5, it was clearly demonstrated that the compounds of the invention effectively protected the neuronal cell death by  $Fe^{2+}$  toxin

**Example 13: Toxicity of the compounds on the neuron cells**

The viability of cortical cell prepared in Example 12-1 was quantified by lactate dehydrogenase (LDH) assay after exposure for 24 hours to the different concentrations of the test compound. Twenty four hours exposure to the compound was done in serum free Eagle's minimal essential medium (MEM) supplemented with 20  $\mu M$  glucose and 38  $mM$  sodium bicarbonate in 5%  $CO_2$  incubator at 37  $^{\circ}C$ . All of compounds were dissolved in DMSO at high concentrations, and then diluted to final concentrations

in the exposure medium at the time of addition.

Measurement of cell death was the same as the method in the Example 12-2.

Fig.6 is a graph showing the level of cell damage as the treatment concentration of Ebbselen increases.

Fig.7 is a graph showing the level of cell damage as the treatment concentration of compound obtained in Example 1 increases.

Fig.8 is a graph showing the level of cell damage as the treatment concentration of compound obtained in Example 2 increases.

Fig.9 is a graph showing the level of cell damage as the treatment concentration of compound obtained in Example 5 increases.

Fig.10 is a graph showing the level of cell damage as the treatment concentration of compound obtained in Example 7 increases.

As can be seen in Figs. 6 to 10, it was clearly determined that the compounds of the invention exhibit lower cytotoxicity than Ebbselen, assuring that they can be administered at large doses in a safe manner.

**Example 14: Protection of cell damage by ischemia (in vivo)**

Male Mongolian gerbils (*Meriones unguiculatus*) weighing 80-88 g were used in the present study. Each animal was medicated P.O. with vehicle, Ebbselen or various test compounds (60 mg/kg in 10% DMSO), after 30 minutes ischemic injury, respectively. 20 animals were allotted into every group. The animals were placed under general anesthesia with a mixture of 2.5% isoflurane in 33% oxygen and 67% nitrous oxide. A midline ventral incision was made in the neck. Both common carotid arteries were isolated, freed of nerve fibers, and occluded using nontraumatic

aneurysm clips. Complete interruption of blood flow was confirmed by observing the central artery in eyeballs using ophthalmoscope. After five minutes of occlusion, the aneurysm clips were removed from both common carotid arteries. Restoration of blood flow (reperfusion) was observed directly under the microscope. Sham-operated controls were subjected to the same surgical procedures except that common carotid arteries were not occluded. Body temperature was monitored and maintained at 37  $^{\circ}C \pm 0.5$   $^{\circ}C$  during surgery and during the immediate postoperative period until the animals recovered fully from anesthesia. At the designated reperfusion time (4 days), operated animals and sham animals were killed.

Animals were perfused transcardially with phosphate-buffered saline (PBS, pH 7.4) followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) at 4 days (n = 7) after surgery. The brains were removed, and postfixed in the same fixative for 4 hours. The brain tissues were cryoprotected by infiltration with 30% sucrose overnight. Corney fixed specimens were cut into 30  $\mu m$  sections on a cryostat, were sequentially stained by Cresyl violet dye.

Images of staining in the hippocampus of each animal were captured with an Applescanner. The brightness and contrast of each image file were uniformly enhanced by Adobe Photoshop version 2.4.1, followed by analysis using NIH Image 1.59 software. All data obtained from the quantitative data were analyzed using one-way ANOVA to determine statistical significance. Bonferroni's test was used for post-hoc comparisons. P values below 0.05 or 0.01 were considered statistically significant.

Fig.11-a is a graph showing the protection level of cell damage in case of the treatment of the compound of the invention after ischemia.

Fig.11-b is a photomicrograph showing the protection level of cell damage in case of the treatment of the

compound of the invention after ischemia.

As the results, the test compound prepared in Example 5 has more neuroprotective effects against ischemic neuronal degeneration than Ebselen. The compound synthesized in Example 5 showed that the protective effects was 61% in post-treated groups. In the Ebselen - treated groups, the effect was 59%.

In conclusion, we suggest that the compound prepared in Example 5 may be a promising candidate as a potential drug for the treatment of ischemia associated diseases.

As clearly described and illustrated above, the present invention provides novel seleno compounds containing nitron moiety, a process for preparing the same, the use of the novel compounds as therapeutics for treating and/or preventing various medical diseases arising from ROS. The compounds of the invention possess similar or superior lipid peroxidation (LPO) inhibition activity to the reference compounds of S-PEN and Ebselen. While showing lower toxicity and better water solubility, they also effectively inhibit the cerebral neuronal cell death caused by ROS and show neuroprotective effects against ischemic neuronal degeneration.

From the foregoing description, various modifications and changes in the compositions and methods of this invention will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein.

L is selected from the group consisting of phenyl, benzyl, ethylphenyl, and heterocyclic unsaturated or saturated radical having 1 to 4 heteroatoms of elements nitrogen, oxygen, and/or sulfur from the group comprising furanyl, oxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, benzothiazolyl, benzotriazolyl, triazolyl, it being possible for the heterocyclic radical to be substituted once or twice, identically or differently, by fluorine, chlorine, bromine, methyl, ethyl, hydroxy, methoxy, ethoxy, methylsulfanyl, phenylsulfanyl, trifluoromethyl, nitro, phenyl, nitrile, carboxy, methoxycarbonyl, or ethoxycarbonyl; and

R<sub>2</sub> is selected from the group consisting of alkyl, substituted alkyl, aralkyl, aryl and cycloalkyl.

3. The compounds according to claim 2, wherein

R<sub>1</sub> and R<sub>2</sub> are selected from the group consisting hydrogen, chlorine, bromine, methyl, ethyl, hydroxy, methoxy, trifluoromethyl, and nitro, or R<sub>1</sub> and R<sub>2</sub> together denote methylenedioxy;

L is selected from the group consisting of phenyl, benzyl, ethylphenyl, and heterocyclic unsaturated or saturated radical having 1 to 4 heteroatoms of elements nitrogen, oxygen, and/or sulfur from the group comprising furanyl, oxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, it being possible for the heterocyclic radical to be substituted once or twice, identically or differently, by chlorine, methyl, methoxy, methylsulfanyl, phenylsulfanyl, trifluoromethyl, nitro, nitrile, carboxy, methoxycarbonyl, or ethoxycarbonyl; and,


R<sub>2</sub> is selected from the group consisting of alkyl, substituted alkyl and cycloalkyl.

4. A process for preparing the compound of formula (II) defined in claim 1, which comprises the following steps of:

(i) reacting N-protected aldehydes having proper

WHAT IS CLAIMED IS:

1. Seleno compounds containing nitron moiety with the following formula (I), and pharmaceutically acceptable salts thereof:



9. A pharmaceutical composition useful as an anti-oxidation agent which comprises as an active ingredient an effective amount of the compound of formula (I) defined in claim 1, in combination with one or more pharmaceutically acceptable carriers or excipients.

10. The pharmaceutical composition according to claim 9, wherein the carrier is an oral carrier.

11. The pharmaceutical composition according to claim 9, wherein the carrier is an injectable carrier.

12. A method for treating a living body afflicted with a condition requiring an antioxidant agent, which comprises a step of administering to the living body an amount of the compound of formula (I) defined in claim 1 which is effective for alleviation of said condition.

13. A method for treating a living body with acute or progressive neurodegenerative disorders, which comprises a step of administering to the living body an amount of the compound of formula (I) defined in claim 1 which is effective for alleviation of said disorders.

14. The method according to claim 13, wherein the acute or progressive neurodegenerative disorders are selected from the group consisting of stroke, Parkinson's disease and Alzheimer's disease.

15. The method according to claim 13, wherein the living body exhibits symptoms of stroke.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11-a



Fig. 11-b

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR2001/01275

A. CLASSIFICATION OF SUBJECT MATTER		
IPC: C07D 293/12		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELD(S) SEARCHED		
Minimum description searched (classification system followed by classification symbols)		
IPC: C07D 293/12		
Description searched other than minimum description to the extent that such documents are included in the ISDB searched		
Documents have been examined during the international search (page of data have not, where practicable, search terms used)		
CASLNO; CAPLUS; MEDLINE; EMBASE/EX		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of documents, with indication, where appropriate, of the relevant passages	Relevance to claim No.
A	Schro G. et al., "Synthesis of 3-Substituted Pyridine Nucleoside Radicals", in: Synthesis 2000, No. 14, pages 2029-2046, see page 2039 and scheme 2	1-15
A	WO 98/03111 A1 (Daiichi Pharma.), 5 March 1998, see the whole document, cited in the application	1-15
A	US 5,006,394 A1 (Bristol-Myers Co. et al.), 16 April 1991, see the whole document, cited in the application	1-15
A	US 5,475,032 A1 (John M. C.), 12 December 1995, see the whole document, cited in the application	1-15
A	EP 947,207 A1 (Adis E. Carapaglia), 29 December 1999, see the whole document	1-15
<input type="checkbox"/> Further documents are listed in the examination of item C. <input checked="" type="checkbox"/> See patent family name.		
* Special category of cited documents: "A" documents defining the general state of the art which is not considered to be of particular relevance "B" documents of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step unless the document is taken into account "C" documents which may throw doubt on priority status or which is cited to establish the publication date of claims or other special cases (as specified) "D" documents relevant to the art, documents, are, available or other name "E" documents published prior to the international filing date but later than the priority date claimed		
* Documents published after the international filing date as priority documents and are to be considered with the application but not to be considered the state of the art for novelty or inventive step purposes "X" documents of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step unless the document is taken into account "Y" documents of particular relevance; the claimed invention cannot be considered to involve an inventive step unless the document is considered with one or more other such documents, priority requirements being deemed to be a patent effect in the art "Z" documents of particular relevance; the claimed invention cannot be considered to involve an inventive step unless the document is considered with one or more other such documents, priority requirements being deemed to be a patent effect in the art		
Date of the actual completion of the international search		Date of mailing of the international search report
23 APRIL 2002 (23.04.2002)		27 APRIL 2002 (27.04.2002)
Name and mailing address of the ISA/ISA		Authorial name
European Intellectual Property Office Casepact Center-Ingolstadt, 82031 Ingolstadt, Germany Deutsche Patent- und Markenamt, 82031 Ingolstadt, Germany Postfach No. 82-43-421-340		LEE, Yn Hyung
Form PCT/ISA/210 (Second sheet) (July 1998)		Telephone No. 82-43-421-340

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB91/01275

## Item 1 Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.: 13-15  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 13-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/compositions.
2. ☐ Claims Nos.:  
because they relate to part of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Item 2 Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Search Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be established without effort justifying an additional fee, this Authority did not require payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remarks on Prior art

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet) (July 1998)

INTERNATIONAL SEARCH REPORT  
Information on patent family membersInternational application No.  
PCT/GB91/01275

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 91/05831 A1	5. 3. 1991	WO 91/05831 A1 EP 826370 A1 US 5948200 A1 AU 3329297 A1 AU 3866997 A1	5. 3. 1991 4. 3. 1991 7. 9. 1999 5. 3. 1998 19. 3. 1998
US 5,001,394 A	16. 4. 1991	JP 0212480 A2 EP 354412 A1	14. 5. 1990 11. 7. 1990
US 5,475,002 A1	12. 12. 1995	WO 95/17876 A2 US 5780510 A1 US 5481145 A1 US 5508305 A1 EP 736004 A1 CN 1156447 A EP 0950723 B2	6. 7. 1995 14. 7. 1998 30. 1. 1996 16. 4. 1996 9. 10. 1996 6. 8. 1997 23. 7. 1997
EP 967,207 A1	29. 12. 1999	CN 1245169 A JP 2000026428 A2 US 6004250 A FR 2780404 A1	23. 3. 2000 25. 1. 2000 7. 3. 2000 31. 12. 1999

Form PCT/ISA/210 (patent family members) (July 1998)